Aurobindo Pharma Ltd.
NSE: AUROPHARMA · Pharmaceuticals
Snapshot
Unlock Aurobindo Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Aurobindo Pharma Limited is a global pharmaceutical company engaged in the research, development, and manufacturing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and finished dosage forms. The company maintains a diverse portfolio spanning therapeutic areas such as cardiovascular, central nervous system, oncology, and anti-retrovirals.
Business Model
The company generates revenue through the large-scale production and export of generic drugs and APIs to multinational partners and global markets. It further leverages custom research and manufacturing services for the biotech sector and invests in complex product pipelines including biosimilars and vaccines.
- Incorporation Year:1986
Growth Outlook
Growth is driven by the expansion of its complex product pipeline, including biosimilars, inhalers, transdermal patches, and vaccines. The company is also focusing on high-value segments like peptides and biocatalysts to enhance its competitive positioning.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from international health authorities, where any non-compliance could lead to import bans or facility inspections.
- Pricing Pressure. Intense competition in the global generic pharmaceutical market often leads to significant price erosion and margin compression.
- Supply Chain Dependency. Reliance on external suppliers for raw materials and APIs exposes the company to potential disruptions in the global supply chain.
- R&D Execution Risk. The successful commercialisation of complex products like biosimilars and vaccines is subject to clinical trial outcomes and lengthy regulatory approval processes.
Start your research today
Unlock AI insights, financials, peers and live data on Aurobindo Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹34,935 Cr
TTM · consolidated
NET PROFIT
₹3,711 Cr
TTM · consolidated
EPS
₹64.00
TTM · consolidated
RETURN ON EQUITY
10.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.4%
TTM · consolidated
P/E
25.8x
Q1 FY27 · consolidated
EV/EBITDA
12.3x
Q1 FY27 · consolidated
EBITDA MARGIN
22.3%
TTM · consolidated
NET PROFIT MARGIN
11.3%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Aurobindo Pharma Ltd.AUROPHARMA | ₹95,116 Cr | 25.83 | 12.30 | 9.1% | 22.3% | 10.5% | 15.4% | +59.6% |
Cipla Ltd.CIPLA | ₹1.12L Cr | 33.18 | 18.12 | 1.8% | 21.6% | 10.2% | 13.6% | -12.2% |
Laurus Labs Ltd.LAURUSLABS | ₹99,334 Cr | 90.82 | 48.68 | 22.6% | 28.7% | 22.3% | 25.3% | +110.5% |
Lupin Ltd.LUPIN | ₹96,476 Cr | 17.44 | 9.81 | 28.2% | 33.4% | 28.0% | 34.5% | +8.8% |
Mankind Pharma Ltd.MANKIND | ₹96,141 Cr | 47.04 | 24.59 | 14.4% | 28.2% | 13.5% | 14.3% | -9.4% |
Dr. Reddy's Laboratories Ltd.DRREDDY | ₹96,070 Cr | 29.75 | 15.36 | -0.9% | 19.8% | 8.9% | 11.4% | -8.1% |
As of Q1 FY27
Financials
Aurobindo Pharma Ltd.
NSE: AUROPHARMA · Pharmaceuticals
Snapshot
Unlock Aurobindo Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Aurobindo Pharma Limited is a global pharmaceutical company engaged in the research, development, and manufacturing of active pharmaceutical ingredients (APIs), generic pharmaceuticals, and finished dosage forms. The company maintains a diverse portfolio spanning therapeutic areas such as cardiovascular, central nervous system, oncology, and anti-retrovirals.
Business Model
The company generates revenue through the large-scale production and export of generic drugs and APIs to multinational partners and global markets. It further leverages custom research and manufacturing services for the biotech sector and invests in complex product pipelines including biosimilars and vaccines.
- Incorporation Year:1986
Growth Outlook
Growth is driven by the expansion of its complex product pipeline, including biosimilars, inhalers, transdermal patches, and vaccines. The company is also focusing on high-value segments like peptides and biocatalysts to enhance its competitive positioning.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from international health authorities, where any non-compliance could lead to import bans or facility inspections.
- Pricing Pressure. Intense competition in the global generic pharmaceutical market often leads to significant price erosion and margin compression.
- Supply Chain Dependency. Reliance on external suppliers for raw materials and APIs exposes the company to potential disruptions in the global supply chain.
- R&D Execution Risk. The successful commercialisation of complex products like biosimilars and vaccines is subject to clinical trial outcomes and lengthy regulatory approval processes.
Start your research today
Unlock AI insights, financials, peers and live data on Aurobindo Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹34,935 Cr
TTM · consolidated
NET PROFIT
₹3,711 Cr
TTM · consolidated
EPS
₹64.00
TTM · consolidated
RETURN ON EQUITY
10.5%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
15.4%
TTM · consolidated
P/E
25.8x
Q1 FY27 · consolidated
EV/EBITDA
12.3x
Q1 FY27 · consolidated
EBITDA MARGIN
22.3%
TTM · consolidated
NET PROFIT MARGIN
11.3%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27